Researchers of the Chromatin and Disease Groupled by Dr. Esteban Ballestar at IDIBELL have identified a distinctive epigenetic event in immune cells that differentiate in the tumoral microenvironment and make them tolerant to cancer cells.
One of the most relevant findings of this study is that the observed epigenetic features of these cells are also present in myeloid-derived suppressor cells isolated from patients with ovarian carcinoma. Given the interest in developing drugs against DNA methyltransferases, the results by this team open up potential therapeutic opportunities for further exploration.